The importance of preventing venous thromboembolism (VTE) in patients undergoing surgery has been widely investigated in the last decade, with good quality clinical trials. The effectiveness of unfractioned heparin (UFH) and low molecular weight heparin (LMWH) in the prevention of pulmonary embolism (PE), one of the leading causes of in-hospital death, has been clearly demonstrated. Indeed, medical patients have not received the same careful attention given to surgical patients despite evidence from clinical studies that 50 to 70% of symptomatic venous thromboembolic events related to hospitalization actually occur in the medical population, and the evidence from autopsy studies that 70 to 80% of all in-hospital deaths related to PE are detected in medical patients. Recent practice audits carried out in Europe and in North America reported a low prescription rate of pharmacological thromboprophylaxis in the medical setting, notwithstanding the publication in the last 6 to 7 years of convincing results from a well known meta-analysis and from a few large randomized controlled trials. All of these showed that in this population either UFH or LMWH are safe and effective in the prevention of VTE. Based on these results, international guidelines have recently begun to recommend the use of pharmacological prophylaxis in acutely ill medical patients, that is to say patients with congestive heart failure, acute respiratory failure, sepsis, cancer, or inflammatory bowel disease.

An additional confirmation of a persistent underuse (and inadequate use) of pharmacological thromboprophylaxis in hospitalized medical patients comes from the study by Rocha and colleagues published in this issue of the Revista da Associação Médica Brasileira. The authors conducted this cross-sectional study aiming to evaluate the adequacy of VTE prophylaxis in medical patients in the Brazilian environment. This study was part of a wider "cultural" sensibilization on the problem of thromboprophylaxis in medical patients, and was conducted prior to implementation of the local recommendations. In the population examined, 97% of the patients had at least one risk factor for VTE, but only 54% received some form of prophylaxis. Adequate doses of pharmacological prophylaxis were administered to 63% of the patients. Prophylaxis was properly conducted in only 33% of the patients. There was no difference in the utilization rate between public and private hospitals. There was a preference for LMWH in private hospitals, especially for patients over 40 years of age and Caucasian patients while UFH was used more often for patients with contraindications to heparin treatment.

Several reasons may explain why pharmacological thromboprophylaxis in acutely ill medical patients remains underused. Concern about bleeding risk and lack of perception that VTE is a "real issue" are presumably the most important causes of underuse. Medical patients often have co-morbidities that further increase bleeding risk or may entail contraindications to pharmacological thromboprophylaxis. These include impaired renal function, previous or active bleeding, concomitant use of antiplatelet drugs, uncontrolled hypertension, or large cerebral ischemic infarctions. Indeed, the benefits of antithrombotic drugs in this high bleeding risk group must be carefully weighed against their potential detriment. However, when pharmacological prophylaxis is unfeasible, mechanical methods such as elastic stockings or intermittent pneumatic compression must be considered. Before deciding against administration of any form of thromboprophylaxis, physicians should be aware that when VTE occurs following hospitalization, the clinical outcome of medical patients is significantly worse than that of surgical patients, for both an increased risk of fatal PE and of fatal/major bleeding events.

A number of critical issues still remain to be addressed. The optimal dosing regimens of LMWH in patients with chronic renal insufficiency have not been adequately evaluated, and the efficacy and safety of reduced dosages, as often suggested, remain unproven. Recommendations for thromboprophylaxis for hospitalized cancer patients are currently the same as for non-cancer patients. However, different types of cancer, different stages of disease, and the various concomitant chemotherapies make cancer patients a very heterogeneous population, probably with different thrombotic and bleeding risks. So far, no studies have been conducted in this specific setting and only approximately 15% of patients enrolled in major clinical trials on the prevention of VTE in medical patients actually had cancer.

In conclusion, VTE in medical patients is a completely preventable disease and is a major threat when it occurs. To reduce this risk, researchers, physicians and health-care-providers should focus their attention on improving individual VTE and bleeding risk stratification, awareness of the problem magnitude, implementation and dissemination of international guidelines, and availability of non-pharmacological prophylactic strategies.

Wider use of adequate prophylactic strategies, both pharmacological and non-pharmacological is warranted, particularly in patients with serious and acute medical conditions.
References